» Articles » PMID: 38491210

Dysregulated N-methyladenosine Modification in Peripheral Immune Cells Contributes to the Pathogenesis of Amyotrophic Lateral Sclerosis

Overview
Journal Front Med
Specialty General Medicine
Date 2024 Mar 16
PMID 38491210
Authors
Affiliations
Soon will be listed here.
Abstract

Amyotrophic lateral sclerosis (ALS) is a progressive neurogenerative disorder with uncertain origins. Emerging evidence implicates N6-methyladenosine (mA) modification in ALS pathogenesis. Methylated RNA immunoprecipitation sequencing (MeRIP-seq) and liquid chromatography-mass spectrometry were utilized for mA profiling in peripheral immune cells and serum proteome analysis, respectively, in patients with ALS (n = 16) and controls (n = 6). The single-cell transcriptomic dataset (GSE174332) of primary motor cortex was further analyzed to illuminate the biological implications of differentially methylated genes and cell communication changes. Analysis of peripheral immune cells revealed extensive RNA hypermethylation, highlighting candidate genes with differential mA modification and expression, including C-X3-C motif chemokine receptor 1 (CX3CR1). In RAW264.7 macrophages, disrupted CX3CR1 signaling affected chemotaxis, potentially influencing immune cell migration in ALS. Serum proteome analysis demonstrated the role of dysregulated immune cell migration in ALS. Cell type-specific expression variations of these genes in the central nervous system (CNS), particularly microglia, were observed. Intercellular communication between neurons and glial cells was selectively altered in ALS CNS. This integrated approach underscores mA dysregulation in immune cells as a potential ALS contributor.

Citing Articles

Loss-of-function variants in RNA binding motif protein X-linked induce neuronal defects contributing to amyotrophic lateral sclerosis pathogenesis.

He D, He X, Shen D, Liu L, Yang X, Hao M MedComm (2020). 2024; 5(9):e712.

PMID: 39263607 PMC: 11387721. DOI: 10.1002/mco2.712.

References
1.
Hardiman O, Al-Chalabi A, Chio A, Corr E, Logroscino G, Robberecht W . Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017; 3:17071. DOI: 10.1038/nrdp.2017.71. View

2.
van Es M, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp R, Veldink J . Amyotrophic lateral sclerosis. Lancet. 2017; 390(10107):2084-2098. DOI: 10.1016/S0140-6736(17)31287-4. View

3.
Brown R, Al-Chalabi A . Amyotrophic Lateral Sclerosis. N Engl J Med. 2017; 377(2):162-172. DOI: 10.1056/NEJMra1603471. View

4.
Feldman E, Goutman S, Petri S, Mazzini L, Savelieff M, Shaw P . Amyotrophic lateral sclerosis. Lancet. 2022; 400(10360):1363-1380. PMC: 10089700. DOI: 10.1016/S0140-6736(22)01272-7. View

5.
Keller M, Ferrucci L, Singleton A, Tienari P, Laaksovirta H, Restagno G . Genome-wide analysis of the heritability of amyotrophic lateral sclerosis. JAMA Neurol. 2014; 71(9):1123-34. PMC: 4566960. DOI: 10.1001/jamaneurol.2014.1184. View